Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer
| Autor: | Pierre-Emmanuel Colombo, Pierre-Jean Lamy, Stéphane Pouderoux, Frédéric Bibeau, William Jacot, Gilles Romieu, Simon Thezenas, Frédéric Montels, Haïdar Saadoun, Marian Gutowski |
|---|---|
| Přispěvatelé: | CRLC Val d'Aurelle-Paul Lamarque, CRLCC Val d'Aurelle - Paul Lamarque, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), Université Montpellier 1 (UM1)-CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Laboratoire de Bioingénierie et NanoSciences (LBN), Université Montpellier 1 (UM1)-Université de Montpellier (UM) |
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Adult Cancer Research medicine.medical_specialty Pathology Multivariate analysis medicine.medical_treatment Decision Making Breast Neoplasms [SDV.CAN]Life Sciences [q-bio]/Cancer Breast Neoplasms/drug therapy/*metabolism/*mortality/pathology Internal medicine Plasminogen Activator Inhibitor 1 medicine 80 and over Chemotherapy Humans Prospective Studies Prospective cohort study Adjuvant Aged Neoplasm Staging Aged 80 and over Univariate analysis business.industry Plasminogen Activator Inhibitor 1/*metabolism Retrospective cohort study General Medicine Middle Aged Prognosis Urokinase-Type Plasminogen Activator 3. Good health Chemotherapy Adjuvant Concomitant T-stage Female business Urokinase-Type Plasminogen Activator/*metabolism |
| Zdroj: | Future Oncology Future Oncology, Future Medicine, 2014, 10, pp.195--209. ⟨10.2217/fon.13.177⟩ |
| ISSN: | 1479-6694 1744-8301 |
| DOI: | 10.2217/fon.13.177⟩ |
| Popis: | ABSTRACT Aims: Following the introduction of new adjuvant therapies we wanted to reappraise the prognostic and predictive value of uPA/PAI-1 in early breast cancer. Patients & methods: This monocentric retrospective study included 652 patients who had curative surgery between 2006 and 2011 and adjuvant treatment decision-making, taking into account uPA/PAI-1 tumor levels. Results: uPA and PAI-1 levels were associated with classical clinicopathological parameters and adjuvant chemotherapy decision, but not with peritumoral vascular invasion (PVI; also known as peritumoral vascular emboli). HER2 overexpression, PVI and uPA/PAI-1 levels were not significantly associated with relapse-free survival in univariate analysis. In multivariate analysis, T stage, N stage and progesterone receptors were the only independent relapse-free survival predictive factors. Conclusion: The absence of an association between uPA/PAI-1 and PVI allows their concomitant consideration in adjuvant treatment discussion. The overall good prognosis of patients with high uPA/PAI-1 levels might be linked to the uPA/PAI-1 predictive value and the inclusion of these parameters in adjuvant guidelines. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|